INDEX OF SUBJECTS FOR VOLUME 37

Abscess
  bactericidal monoglyceride in staphylococcal abscesses, 238
Acinetobacter baumanii
  treatment of infection by phages, 258
Adherence
  biofilm formation by coagulase-negative staphylococci, 62
  E. coli to rabbit intestinal cells, 304
  haemagglutinating activity of *Helicobacter* spp., 299
Aerobactin, 15
Aeromonas spp.
  antibiotic susceptibility, 315
  enterotoxicity, 262
  haemolysins, 262
  role in gastro-enteritis in children, 315
Agglutination
  lectin-binding assay of *S. epidermidis*, 195
  lectins, by gonococci, 51
AIDS patients, and candidosis, 225
Air sampling, in hospitals, 81
Albendazole, susceptibility of *G. lamblia*, 221
Amoxycillin, and β-lactamases, 297
Anaerobes
  classification of oral non-pigmented bacilli, 83, 273
  classification of oral pigmented bacilli, 56
  detection of bacteraemias, 410
  gram-negative, 56, 83, 273
  see also Bacteroides
Antibiotic resistance
  amoxycillin, and β-lactamases, 297
  azole drugs, and *Candida* spp., 225
  cephalosporins, and *E. cloacae*, 91
  clavulanic acid, and β-lactamases, 297
  in epidemiology of staphylococci, 109
  fluconazole, and *Candida* spp., 225
  itraconazole, and *Candida* spp., 225
  ketoconazole, and *Candida* spp., 225
  and β-lactamase inhibitors, 297
  methicillin, and *S. aureus*, 187
  penicillin, and *N. gonorrhoeae*, 96
  plasmid transfer, and staphylococci, 180
Antibiotics and other antimicrobial substances
  albendazole, and *G. lamblia*, 221
  chloramphenicol, and biofilm formation, 62
  chloramphenicol and Mediterranean Spotted Fever, 153
  5-fluorouracil, and biofilm formation, 62
  mebendazole, and *G. lamblia*, 221
  5-nitroimidazoles, and *G. lamblia*, 221
  susceptibility of *Aeromonas* spp., 315
  susceptibility of *Salmonella* of serotype Typhimurium, 252
  tetracycline, and Mediterranean Spotted Fever, 153
  tunicamycin, and biofilm formation, 62
Antibodies
  against hepatotoxigenic factor of *C. jejuni*, 326
  against hydatid-specific antigens, 396
  against *S. aureus*, 227, 376
  against verotoxin-producing *E. coli*, 364
  see also Monoclonal antibodies
Antigens
  of *Brucella*, 100
  extracellular proteins of *S. aureus*, 227
  in giardiasis, 1
  hydatid-specific, 396
  of *L. pneumophila*, 155
  outer envelope of *S. hyodysenteriae*, 214
  of *P. shigelloides*, 382
  polypeptides of *H. ducreyi*, 413
  S. milleri carbohydrate type, 211
  of *S. sonnei*, 382
  of *T. gondii*, 404
  of verotoxin-producing *E. coli*, 364
Antisera
  against *S. milleri* type antigens, 211
Antitoxin
  against *E. coli* enterotoxin, 22
Aspergillus spp., in nosocomial infections, 81
Autophagosomes, 389
Azole drugs, resistance of *Candida* spp., 225

Bacillus piliformis, cytopathic effects, 77
Bactec system, 332, 410
Bacteraemia
  anaerobic, detection of, 410
  streptococcal, detection of, 410
Bacterial vaginosis, 38
Bacteriophages *see* Phages
Bacteroides
  B. distasonis, outer-membrane protein, 165
  B. distasonis, pore-forming activity, 165
Biochemical tests
  classification of oral anaerobic bacilli, 56, 83
  Phene Plate system for *Salmonella* of serotype Typhimurium, 245, 252
Biofilm
  formation by coagulase-negative staphylococci, 62
Biotinylation, 420
Biotyping
  coagulase-negative staphylococci, 109
Blood culture
  "*C. upsaliensis*", 8
  detection of bacteraemias, 409
Bone infection, *S. aureus*, 227
BOOKS RECEIVED
  Anaerobic Microbiology: A Practical Approach (Edited by P. N. Levett), 154
  The Biology of Acinobacter (Edited by K. J. Towner *et al.*), 360
  CAPD: Host Defence, Nutrition and Ultrafiltration (Edited by G. A. Coles, M. Davies and J. D. Williams), 150
  Current Investigations of the Microbiology of Yersiniae. Volume 12 of Contributions to Microbiology and Immunology (Edited by T. Une, T. Maruyama and M. Tsubokura), 152
  Current Topics in Microbiology and Immunology, Volume 169, Bunyaviridae (Edited by D. Kolakofsky), 150
  ELISA in the Clinical Microbiology Laboratory (Edited by T. G. Wreghitt and P. Morgan-Capner), 152
  Foodborne Pathogens. An Illustrated Text (A. H. Varnam and M. G. Evans), 154
  Fungal Infection in the Compromised Patient, 2nd edition (Edited by D. W. Warnock and M. D. Richardson), 151
  Genetic Structure and Regulation of HIV. Harvard AIDS Institute Series on Gene Regulation of Human Retroviruses, Volume 1 (Edited by W. A. Haseltine and Flossie Wong-Staal), 151
  Medical Microbiology. An Introduction to Infectious Diseases, 2nd edition (Edited by J. C. Sherris), 150
  Medical Virology 10 (Edited by L. M. De La Maza and Ellena M. Peterson), 224
  Microbial Cell Surface Analysis. Structural and Physiochemical Methods. (Edited by N. Mozes *et al.*), 295
  Modern Microbial Genetics (Edited by U. N. Streips and R. E. Yasbin), 152
  Multipoint Methods in the Clinical Laboratory (M. Faiers, F. George, J. Jolly and P. Wheat), 150
  New Antibacterial Strategies (Edited by H. C. Neu), 151
Branhamella catarrhalis see Moraxella catarrhalis
Brucella
  immune response in mouse model, 100
  monoclonal antibodies, 100

Caco-2 cells, invasion by campylobacters, 319
Calcium ionophore, 238
Campylobacters
  C. coli, invasion of cell cultures, 319
  C. jejuni, cytotoxin, 22
  C. jejuni, enterotoxin, 22

C. jejuni hepatotoxigenic factor, 326
C. jejuni, interaction with cell cultures, 22, 30
C. jejuni, invasion of cell cultures, 30, 319
C. jejuni, ribotyping, 385
C. jejuni, virulence factors, 22, 30
C. pylori see Helicobacter pylori
"*C. upsaliensis*", plasmid profiles, 8
improved isolation from diarrhoeal stools, 176
Candida spp.
azole drug resistance, 225
C. albicans, detection by DNA probes, 346
C. albicans, disseminated candidosis, 291, 346
C. albicans, tissue trophism, 291
detection by DNA probes, 346
Candidosis, 225, 291, 346
Carotenoid pigment levels, in *S. aureus*, 192
Cefotaxime resistance, of *E. cloacae*, 91
Cefoxitin resistance, of *E. cloacae*, 91
Ceftazidime resistance, of *E. cloacae*, 91
Cell culture
association of *H. ducreyi*, 268
cytopathic effects of *B. piliformis*, 77
cytopathic effects of *H. ducreyi*, 43
cytopathic effects of *H. pylori*, 118
cytotoxic effects of *C. jejuni*, 22
interaction with *C. jejuni*, 30
intracytoplasmic vacuolation by *H. pylori*, 389
invasion by *C. jejuni* and *C. coli*, 319
of rickettsiae, 153
virulence-associated properties of *E. coli*, 310
virulence-associated properties of *H. alvei*, 310
Cephaloridine resistance, of *E. cloacae*, 91
Cephalosporins
extended-spectrum, 297
susceptibility of *E. cloacae*, 91
Chloramphenicol
and biofilm formation by staphylococci, 62
and Mediterranean Spotted Fever, 153
Chloroform-phenol lysis method, 8
Chromatography
gas-liquid, 83
gel, 367
ion-exchange, 195, 367
thin layer, 238, 286
Clavulanic acid, and β-lactamases, 297
Clostridia
C. difficile, cytotoxin production, 206
C. difficile, nosocomial infection, 352
C. difficile, sporulation, 206
C. perfringens, bacterial air counts in hospitals, 81
C. perfringens, post-operative wound infection, 81
Colitis, and pathogenicity of campylobacters, 319
Concanavalin A, binding by *S. epidermidis*, 195
Continuous ambulatory peritoneal dialysis, 109
Cytochromes, of *H. influenzae*, 133
Cytotoxins
of *B. piliformis*, 77
of *C. difficile*, 206
of *C. jejuni*, 22
of *H. pylori*, 118, 389

Diarrhoea
campylobacter-induced, 22
and enteropathogenic *E. coli*, 310
in giardiasis, 1
and *H. alvei*, 310
isolation of *Campylobacter* spp., 176
pathogenicity of campylobacters, 319
role of *Aeromonas* spp. in gastro-enteritis, 315
DNA
hybridisation, 141, 304, 310, 346, 357
plasmid profile analysis, 8, 104
restriction analysis, 70, 155, 162, 187
yeast-specific probes, 346

Echinococcus granulosus, 396
Elastase, of *S. epidermidis*, 201
Electronmicroscopy
adherence of *E. coli*, 304
H. ducreyi in cell culture, 43, 268
phagocytosis of *P. cepacia* by alveolar macrophages, 335
scanning, 304, 335
transmission, 43, 268, 335
vacuolation of cell cultures by *H. pylori*, 389
Electrophoresis
multilocus enzyme, 96
pulsed field gel, 187
see also PAGE, SDS–PAGE
ELISA
detection of antibodies to verotoxin-producing *E. coli*, 364
diagnosis of acute toxoplasmosis, 404
diagnosis of hydatidosis, 396
micro-ELISA, 396
recombinant antigen, 404
Enteritis, *C. jejuni* infection, 385
Enterobacter cloacae
cephalosporin resistance, 91
β-lactamase expression, 91
plasmids, 91
Enterochelin, 15
Enterotoxins
of *Aeromonas* spp., 262
of *C. jejuni*, 22
and pathogenicity of campylobacters, 319
Enzyme-linked ligand binding assay (ELBA), 341
Epidemiology
C. jejuni enteritis, 385
characterisation of *S. typhimurium*, 104
coagulase-negative staphylococci, 109
of gonococcal serovars, 51
methicillin-resistant *S. aureus*, 187
nosocomial *C. difficile* infection, 352
S. pyogenes pharyngitis, 162
Salmonella of serotype Typhimurium, 245, 252
Escherichia coli
adherence, 304, 310
bactericidal effects of serum, 3
detection of lactoferrin binding, 341
enteropathogenic (EPEC), 15, 310
enterotoxigenic (ETEC), 141
fimbriae, 304
haemolysins, 3
in haemolytic uraemic syndrome, 364
iron uptake mechanisms, 15
β-lactamase, 297
lipopolysaccharide, 364
phagocytosis by PMNLs, 3
plasmids, 141, 304
sharing of virulence-associated properties with *H. alvei*, 310
verocytotoxin-producing, 304, 364
virulence factors, 3, 304, 310

Faeces
"*C. upsaliensis*" isolates, 8
isolation of *Aeromonas* spp. in gastro-enteritis, 315
Fatty acid modifying enzyme (FAME), 232, 235
Fatty acids
esterification by *S. aureus* fatty acid modifying enzyme, 235
Fibronectin
binding by lactobacilli, 38
S. aureus fibronectin-binding protein, 376
Filtration technique
isolation of *Campylobacter* spp. from faeces, 176
Fimbriae, of *E. coli*, 304
Fluconazole, susceptibility of *Candida* spp., 225
Fluorescent staining, 310, 389
5-Fluorouracil
and biofilm formation by staphylococci, 62

Gastritis, 299
Gastro-enteritis
role of *Aeromonas* spp., 315
Gene
probe, plasmid-encoded toxins of *E. coli*, 141
sharing of virulence-associated properties of *E. coli* and *H. alvei*, 310
stable derepression of β-lactamase, 91
Giardia lamblia
clinical diversity, 1
immune response, 1

pathogenesis, 1
susceptibility to chemotherapeutic agents, 221
Glucose, metabolism by *H. influenzae*, 133
Gonococci, *see Neisseria gonorrhoeae*
Guillain-Barré syndrome, 326

Haem, iron uptake by *E. coli*, 15
Haemagglutination
indirect test, for rickettsiae, 153
red blood cells by *Helicobacter* spp., 299
Haemin, effects on metabolism of *H. influenzae*, 133
Haemoglobin, iron uptake by *E. coli*, 15
Haemolysins
of *Aeromonas* sp., 262
of *E. coli*, 3
Haemolytic uraemic syndrome, 364
Haemophilus
H. ducreyi, in cell culture, 43, 268
H. ducreyi, monoclonal antibodies, 413
H. ducreyi, species-specific polypeptides, 413
H. ducreyi, virulence factors, 268, 413
H. influenzae, cytochromes, 133
H. influenzae, metabolism of haemin-limited organisms, 133
Hafnia alvei
sharing of virulence-associated properties with *E. coli*, 310
Helicobacter pylori
adherence, 299
cytopathic effects, 118
cytotoxin, 389
haemagglutination profiles, 299
intracytoplasmic vacuolation, 389
motility as a colonisation factor, 123
urease activity, 118
haemagglutination profiles, 299
Hepatitis, *C. jejuni*-induced, 326
HIV infection, 225, 385
Hybridisation of DNA
diagnosis of typhus infection, 358
gene probe assay of *E. coli*, 141
plasmid profiles and virulence of *E. coli*, 304, 310
shared virulence-associated properties of *E. coli* and *H. alvei*, 310
yeast-specific probes, 346
Hydatidosis, diagnosis, 396

Ileal loops
attaching-effacing lesions and *E. coli*, 310
attaching-effacing lesions and *H. alvei*, 310
enterotoxicity of *Aeromonas* spp., 262
Immune complexes, in hydatidosis, 396
Immune response
in giardiasis, 1
to anti-*Brucella* monoclonal antibodies, 100
to *S. aureus* fibronectin-binding protein, 376
Immunisation
mice against *Brucella*, 100
mice against *S. aureus* fibronectin-binding protein, 376
rabbits against *S. sonnei*, 382
Immunoblotting
characterisation of *M. catarrhalis* isolates, 70
extracellular protein antigens of *S. aureus*, 227
typing of coagulase-negative staphylococci, 109
Immunoglobulins
in giardiasis, 1
IgA, cleavage by *P. multocida* protease, 128
IgG, cleavage by *P. multocida* protease, 128
IgG, in *S. aureus* bone infection, 227
Immunosuppression, and nosocomial infections, 81
Iron
limitation and *E. coli*, 15
uptake mechanisms of *E. coli*, 15
Iso-electric focusing, 91
Itraconazole, susceptibility of *Candida* spp., 225

Ketoconazole, susceptibility of *Candida* spp., 225

β-Lactamases
cephalosporin resistance of *E. cloacae*, 91
and β-lactamase inhibitors, 297
stable derepression, 91
Lactobacilli
in bacterial vaginosis, 38
fibronectin binding, 38
Lactoferrin, interaction with bacteria, 341
Lectins
agglutination by gonococci, 51
binding assay for *S. epidermidis*, 195
Legionella pneumophila
relationship between genotype and serogroup, 155
Lipase
of *P. cepacia*, 335
production by staphylococci, 232
Lipopolysaccharide (LPS)
of *Brucella*, 100
of *E. coli*, 364
Lymphocyte proliferation assay, 283

Macrophages
alveolar, phagocytosis of *P. cepacia*, 335
Mantoux test, 283
MB Check mycobacterial culture system, 332
Mebendazole, susceptibility of *G. lamblia*, 221
Media
biphasic system for isolation of mycobacteria, 332
blood culture systems for detection of bacteraemias, 409
for isolation of campylobacters from faeces, 176
Methicillin resistance of *S. aureus*, 187
Micro-enzyme-linked immunosorbent assay (Micro-ELISA), 396
Monoclonal antibodies
against *Brucella*, 100
against *H. ducreyi*, 413
against *N. gonorrhoeae*, 51
against *S. hyodysenteriae*, 214
Moraxella (*Branhamella*) *catarrhalis*
nosocomial infection, 70
typing and characterisation, 70
Motility
as a colonisation factor for *H. pylori*, 123
Mouse model
C. jejuni-induced hepatic lesions, 326
immunisation against *Brucella*, 100
treatment of infections with phages, 258
Mycobacteria
biphasic system for primary isolation, 332
M. tuberculosis, screening tests for infection, 283
rapid identification using mycobactin, 286
Mycobactin, 286

Neisseria gonorrhoeae
lectin agglutination, 51
monoclonal antibodies, 51
penicillin resistance, 96
penicillinase non-producing strains, 96
serotyping, 51
5-Nitroimidazoles, and *G. lamblia*, 221
Nosocomial infection
air sampling in hospitals, 81
C. difficile, 352
M. catarrhalis, 70

Oleic acid, sensitivity of *S. aureus*, 192
Opsonophagocytosis, of *P. cepacia*, 335
Oral microflora
classification of anaerobic bacilli, 56, 83, 273
detection of bacteraemias, 410
distribution of *S. milleri* type antigens, 211
Ovotransferrin, 15
Oxoid Signal system, 410

PAGE
genetic variability of penicillinase non-producing strains of *N. gonorrhoeae*, 96
see also SDS–PAGE
Pasteurella multocida, protease production, 128
Penicillin resistance of *N. gonorrhoeae*, 96
Peritonitis, 109

Phages
  reverse phage typing, 109
  in treatment of experimental infections, 258
  typing of coagulase-negative staphylococci, 109
  typing of *S. typhimurium*, 104
  typing of *Salmonella* of serotype Typhimurium, 245, 252
Phagocytosis
  E. coli by polymorphonuclear leucocytes, 3
  P. cepacia by alveolar macrophages, 335
Pharyngitis, *S. pyogenes* in, 162
Phene Plate (PhP) system, 245, 252
Piglets, gnotobiotic, 123
Plasmids
  antibiotic resistance of staphylococci, 180
  cephalosporin resistance in *E. cloacae*, 91
  of enterotoxigenic *E. coli*, 141
  and β-lactamase inhibitors, 297
  mobilisation of non-conjugative plasmids in staphylococci, 180
  plasmid profiles of "*C. upsaliensis*", 8
  plasmid profiles of coagulase-negative staphylococci, 109
  plasmid profiles of *E. coli*, 304
  plasmid profiles of *S. typhimurium*, 104
Plesiomonas shigelloides
  vaccine, cross-protection against *S. sonnei*, 381
Polymerase chain reaction
  diagnosis of typhus infection, 357
Polymorphonuclear leucocytes (PMNLs)
  phagocytosis of *E. coli*, 3
Pore-forming activity, of *B. distasonis*, 165
Porphyromonas spp.
  classification of oral isolates, 56
  pyrolysis mass spectrometry, 56
Prevotella spp.
  classification, 56, 83, 273
  pyrolysis mass spectrometry, 56, 273
Protease
  cleavage of IgA and IgG, 128
  production by *P. multocida*, 128
  of *S. epidermidis*, 195
Proteins
  extracellular antigens of *S. aureus*, 227
  immunogenic, of *R. tsutsugamushi*, 357
  outer-membrane, of *B. distasonis*, 165
  outer-membrane of *Brucella*, 100
  outer-membrane of *Y. pestis*, 419
  pore-forming activity of *B. distasonis*, 165
  S. aureus fibronectin-binding protein, 376
  whole-cell protein profiles of *Prevotella* spp., 83
  whole-cell protein typing of coagulase-negative staphylococci, 109
  whole-cell protein typing of *M. catarrhalis*, 70
Pseudomonas
  P. aeruginosa, treatment of infection by phages, 258
  P. cepacia lipase, 335
  P. cepacia, phagocytosis by alveolar macrophages, 335
Pyrolysis mass spectrometry
  C. difficile, 352
  Porphyromonas spp., 56
  Prevotella spp., 56, 273

Radiolabelling techniques, 62, 165, 291, 304, 341, 420
Rat model, disseminated candidosis, 291
Reiter's syndrome, 326
Restriction analysis, typing of *M. catarrhalis*, 70
Restriction fragment length polymorphism typing
  of *L. pneumophila*, 155, 162
  methicillin-resistant *S. aureus*, 187
Ribotyping
  C. jejuni, 385
  S. pyogenes, 162
Rickettsiae
  R. conorii, in Spotted Fever, 153
  R. tsutsugamushi, rapid diagnosis, 358

Saccharomyces cerevisiae, yeast-specific probe, 346
Salmonellae
  antimicrobial-susceptibility testing, 252
  nomenclature, 361
  S. typhimurium, phage typing, 104
  S. typhimurium, plasmid profile analysis, 104
  serotype Typhimurium, biochemical-fingerprint typing, 245, 252
  serotype Typhimurium, phage typing, 245, 252
Scrub typhus disease, 357
SDS–PAGE
  classification of *Prevotella* spp., 273
  outer-membrane protein of *B. distasonis*, 165
  whole-cell proteins of coagulase-negative staphylococci, 109
  whole-cell proteins of *M. catarrhalis*, 70
  whole-cell proteins of *Prevotella* spp., 83
Serogrouping, of *L. pneumophila*, 155
Serology, diagnosis of Spotted Fever, 153
Serotyping, *N. gonorrhoeae*, 51
Serpulina (*Treponema*) *hyodysenteriae*
  monoclonal antibodies, 214
  outer-envelope antigen, 214
Serum
  in acute toxoplasmosis, 404
  antibodies to *S. aureus* bone infection, 227
  bactericidal effects against *E. coli*, 3
  in haemolytic uraemic syndrome, 364
  in hydatidosis, 396
Shigella sonnei
  immune protection against, 382
Siderophores, 15
Slime production
  by coagulase-negative staphylococci, 62, 368
Southern blotting, 357, 385
Spore production, by *C. difficile*, 206
Spotted Fever, 153
Staphylococci
  biofilm production, 62
  cell-wall teichoic acid, 367
  coagulase-negative, 62, 109, 195, 232, 368
  epidemiology, 109
  evaluation of typing methods, 109
  lipase production, 232
  plasmids, 180
  production of fatty acid modifying enzyme, 232, 235
  S. aureus, air counts in hospital, 81
  S. aureus, bone infection, 227
  S. aureus, carotenoid pigment levels, 192
  S. aureus, epidemiology, 187
  S. aureus, extracellular protein antigen, 227
  S. aureus, fatty acid modifying enzyme, 235
  S. aureus, fibronectin-binding protein, 376
  S. aureus, methicillin-resistant, 187
  S. aureus, post-operative wound infection, 81
  S. aureus, production of bactericidal lipid in abscesses, 238
  S. aureus, sensitivity to oleic acid, 192
  S. aureus, treatment of infection by phages, 258
  S. epidermidis, elastase, 195
  S. epidermidis, slime production, 367
  S. epidermidis, typing by lectin-binding assay, 195
  slime production, 62
  transfer of antibiotic resistance, 180
Streptococci
  detection of bacteraemias, 409
  S. milleri carbohydrate type antigens, 211
  S. pyogenes, in pharyngitis, 162
  viridans, 211
Sulbactam, and β-lactamases, 297

Taxonomy
  oral gram-negative anaerobic bacilli, 56, 83, 273
Tazobactam, and β-lactamases, 297
Tetracycline, and Mediterranean Spotted Fever, 153
Ticarcillin, and β-lactamases, 297
Tick-borne fever, 153
Toxins
  hepatotoxigenic factor of *C. jejuni*, 326
  see also Cytotoxins, Enterotoxins
Toxoplasma gondii
  antigens, 404
  diagnosis of infection, 404
Toxoplasmosis, acute, 404
Treponema hyodysenteriae see Serpulina hyodysenteriae
Tsutsugamushi disease, 357
Tuberculin skin test, 283
Tuberculosis, screening tests, 283

Tunicamycin, and biofilm formation by staphylococci, 62
Tyzzer's disease, 77

Urease activity, of *H. pylori*, 118

Vaccine, against *S. sonnei*, 382
Verocytotoxins, 304, 364
Virulence factors
  C. jejuni, 22, 30
  E. coli, 3, 304, 310
  H. alvei, 310
  H. ducreyi, 268, 413
  Helicobacter spp., 299
  P. cepacia, 335
  P. multocida, 128
  S. epidermidis, 195

Western blotting, 165, 376
Wound infections, post-operative, 81

Yeast-specific DNA probes, 346
Yersinia pestis, surface-exposed proteins, 420

INDEX OF AUTHORS FOR VOLUME 37

ABATH F G C, ALMEIDA A M P, FERREIRA L C S. Identification of surface-exposed *Yersinia pestis* proteins by radioiodination and biotinylation, 420
ALAM K, *see* ALBERT *et al.*, 310
ALBERS W, *see* LONG *et al.*, 232
ALBERT M J, FARUQUE S M, ANSARUZZAMAN M, ISLAM M M, HAIDER K, ALAM K, KABIR I, ROBINS-BROWNE R. Sharing of virulence-associated properties at the phenotypic and genetic levels between enteropathogenic *Escherichia coli* and *Hafnia alvei*, 310
ALBERT M J, TEE W, LEACH A, ASCHE V, PENNER J L. Comparison of a blood-free medium and a filtration technique for the isolation of *Campylobacter* spp. from diarrhoeal stools of hospitalised patients in central Australia, 176
ALFA M J. Cytopathic effect of *Haemophilus ducreyi* for human foreskin cell culture, 43
ALFA MICHELLE J, YANG CHUN-LIN, SLANEY L A, KWOK ANITA Y C, RONALD A R, JAY F T. Identification of highly conserved and species-specific polypeptides of *Haemophilus ducreyi*, 413
ALMEIDA A M P, *see* ABATH *et al.*, 420
AMYES S G B, *see* THOMSON AND AMYES, 297
ANDRE P M, *see* POUEDRAS *et al.*, 128
ANSARUZZAMAN M, *see* ALBERT *et al.*, 310
ANTILLON FLORENCIA, *see* FLORIN AND ANTILLON, 22
ASCHE V, *see* ALBERT *et al.*, 176
ASHKENAZI S, LAROCCO H, MURRAY B E, CLEARY T G. The adherence of verocytotoxin-producing *Escherichia coli* to rabbit intestinal cells, 304
AVRIL J L, *see* POUEDRAS *et al.*, 128
AZIZI E, *see* GLUSKIN *et al.*, 315

BAGGA A, *see* KISHORE *et al.*, 364
BAIN MARION, *see* MCKENZIE *et al.*, 70
BARCLAY R, FURST VANESSA, SMITH I. A simple and rapid method for the detection and identification of mycobacteria using mycobactin, 286
BATASH D, *see* GLUSKIN *et al.*, 315
BERTIN A. Plasmid content and localisation of the STaI (STaP) gene in enterotoxigenic *Escherichia coli* with a non-radioactive polynucleotide gene probe, 141
BINGEN E, DENAMUR E, LAMBERT-ZECHOVSKY N, BRAIMI N, EL LAKANY M, ELION J. DNA restriction fragment length polymorphism differentiates recurrence from relapse in treatment failures of *Streptococcus pyogenes* pharyngitis, 162
BOLDUR I, *see* GLUSKIN *et al.*, 315
BRAIMI N, *see* BINGEN *et al.*, 162
BROWN M R W, *see* O'REILLY *et al.*, 133
BUTZLER J-P, *see* EVEREST *et al.*, 319

CAFFREY C J, *see* RILEY *et al.*, 77
CANNON R D, *see* HOLMES *et al.*, 346
CARTMILL T D I, ORR K, FREEMAN R, SISSON P R, LIGHTFOOT N F. Nosocomial infection with *Clostridium difficile* investigated by pyrolysis mass spectrometry, 352
CATRENICH C E, CHESTNUT M H. Character and origin of vacuoles induced in mammalian cells by the cytotoxin of *Helicobacter pylori*, 389
CEDILLO-RIVERA R, MUÑOZ O. In-vitro susceptibility of *Giardia lamblia* to albendazole, mebendazole and other chemotherapeutic agents, 221
CHESTNUT M H, *see* CATRENICH AND CHESTNUT, 389
CIBOROWSKI P, FLOCK J-I, WADSTRÖM T. Immunological response to a *Staphylococcus aureus* fibronectin-binding protein, 376
CIEPLAK W, *see* KONKEL *et al.*, 30
CLEARY T G, *see* ASHKENAZI *et al.*, 304
CLOECKAERT A, *see* JACQUES *et al.*, 100
COCUZZA CLEMENTINA. Spotted Fever in the Mediterranean, 153
COLLINS C, *see* HUSSAIN *et al.*, 62
COOKSON B, *see* DRYDEN *et al.*, 109
CORWIN M D, *see* KONKEL *et al.*, 30
CUNNINGHAM M, *see* DRYDEN *et al.*, 109

DA SILVA TATLEY FERNANDA M, LASTOVICA A J, STEYN L M. Plasmid profiles of "*Campylobacter upsaliensis*" isolated from blood cultures and stools of paediatric patients, 8
DAVIES H A, *see* SHAH *et al.*, 268
DE LA FUENTE L, VÁZQUEZ J A. Analysis of genetic variability of penicillinase non-producing *Neisseria gonorrhoeae* strains with different levels of resistance to penicillin, 96
DENAMUR E, *see* BINGEN *et al.*, 162
DONNIO P Y, *see* POUEDRAS *et al.*, 128
DOSHI N, *see* HARRISON *et al.*, 155
DRYDEN M S, TALSANIA H G, MARTIN S, CUNNINGHAM M, RICHARDSON J F, COOKSON B, MARPLES R R, PHILLIPS I. Evaluation of methods for typing coagulase-negative staphylococci, 109
DUBRAY G, *see* JACQUES *et al.*, 100
DUERDEN B I, *see* MAGEE *et al.*, 56, 273
DUERDEN B I, *see* YOUSEFI-MASHOUF *et al.*, 83
DWYER B, *see* TEE *et al.*, 385

EATON K A, MORGAN D R, KRAKOWKA S. Motility as a factor in the colonisation of gnotobiotic piglets by *Helicobacter pylori*, 123
EL LAKANY M, *see* BINGEN *et al.*, 162
ELEY A, *see* YOUSEFI-MASHOUF *et al.*, 83
ELION J, *see* BINGEN *et al.*, 162
ENGLER H D, KAPRAL F A. The production of a bactericidal monoglyceride in staphylococcal abscesses, 238
ENRIGHT M C, *see* MCKENZIE *et al.*, 70
ERDEI J, *see* KISHORE *et al.*, 341
ESPERSEN F, *see* JARLØV *et al.*, 195
EVEREST P H, GOOSSENS H, BUTZLER J-P, LLOYD D, KNUTTON S, KETLEY J M, WILLIAMS P H. Differentiated Caco-2 cells as a model for enteric invasion by *Campylobacter jejuni* and *C. coli*, 319

FANTASIA MIRELLA, *see* MARTINI *et al.*, 104
FARHOUDI-MOGHADDAM A A, *see* KATOULI *et al.*, 252
FARTHING M J G. New perspective in giardiasis, 1
FARUQUE S M, *see* ALBERT *et al.*, 310
FERREIRA L C S, *see* ABATH *et al.*, 420
FIAVEY N P, FRANKENBURG S. Appraisal of the total blood lymphocyte proliferation assay as a diagnostic tool in screening for tuberculosis, 283
FILETICI EMMA, *see* MARTINI *et al.*, 104
FISHER G, *see* WEXLER *et al.*, 165
FLOCK J-I, *see* CIBOROWSKI *et al.*, 376
FLORIN INGER, ANTILLON FLORENCIA. Production of enterotoxin and cytotoxin in *Campylobacter jejuni* strains isolated in Costa Rica, 22
FOLKENING W J, *see* KATZ *et al.*, 291
FORSGREN A, *see* KISHORE *et al.*, 341
FOX J G, *see* TAYLOR *et al.*, 299
FRANKENBURG S, *see* FIAVEY AND FRANKENBURG, 283
FREEMAN R, *see* CARTMILL *et al.*, 352
FREEMAN R, *see* LAW *et al.*, 15
FRÖMAN G, *see* NAGY *et al.*, 38
FURST VANESSA, *see* BARCLAY *et al.*, 286

GATERMANN S, *see* SLOOT *et al.*, 201
GETTY C, *see* WEXLER *et al.*, 165
GLUSKIN I, BATASH D, MOR A, KAZAK R, AZIZI E, BOLDUR I. A 15-year study of the role of *Aeromonas* spp. in gastro-enteritis in hospitalised children, 315
GOODWIN L, *see* MAGEE *et al.*, 56
GOOSSENS H, *see* EVEREST *et al.*, 319
GOULD F K, *see* LAW *et al.*, 15
GROSFELD J L, *see* KATZ *et al.*, 291
GRUBB W B, *see* UDO *et al.*, 180
GRUBB W B, *see* WEI AND GRUBB, 187

HAIDER K, *see* ALBERT *et al.*, 310
HAILE M, *see* HOFFNER *et al.*, 332
HANSEN J-E S, *see* JARLØV *et al.*, 195

HARRISON T G, SAUNDERS N A, HATHTHOTUWA A, DOSHI N, TAYLOR A G. Further evidence that genotypically closely related strains of *Legionella pneumophila* can express different serogroup specific antigens, 155
HART J, *see* LONG *et al.*, 232
HASTINGS J G M, *see* HUSSAIN *et al.*, 62, 368
HASUBSKI ANNA T, *see* TAYLOR *et al.*, 299
HATHTHOTUWA A, *see* HARRISON *et al.*, 155
HINDMARCH J M, *see* MAGEE *et al.*, 56, 273
HOFFNER S E, HAILE M, KÄLLENIUS G. A biphasic system for primary isolation of mycobacteria compared to solid medium and broth culture, 332
HOLMES A R, LEE Y C, CANNON R D, JENKINSON H F, SHEPHERD M G. Yeast-specific DNA probes and their application for the detection of *Candida albicans*, 346
HUMPHREYS HILARY. Microbes in the air—when to count! (The role of air sampling in hospitals), 81
HUSSAIN M, COLLINS C, HASTINGS J G M, WHITE P J. Radiochemical assay to measure the biofilm produced by coagulase-negative staphylococci on solid surfaces and its use to quantitate the effects of various antibacterial compounds on the formation of the biofilm, 62
HUSSAIN M, HASTINGS J G M, WHITE P J. Comparison of cell-wall teichoic acid with high-molecular-weight extracellular slime material from *Staphylococcus epidermidis*, 368
HUTCHINSON NICOLETTE A, THOMAS F D, SHANSON D C. The clinical comparison of Oxoid Signal with Bactec blood culture systems for the detection of streptococcal and anaerobic bacteraemias, 410
HUTSON J C, *see* STRAUS *et al.*, 335

INOUE M, MATSUNOSHITA NOBUKO, YAKUSHIJI T. Restricted distribution of *Streptococcus milleri* carbohydrate type antigens amongst other viridans streptococci, 211
ISHIBASHI M, *see* KONISHI *et al.*, 118
ISLAM M M, *see* ALBERT *et al.*, 310

JACQUES I, CLOECKAERT A, LIMET J N, DUBRAY G. Protection conferred on mice by combinations of monoclonal antibodies directed against outer-membrane proteins or smooth lipopolysaccharide of *Brucella*, 100
JARLØV J O, HANSEN J-E S, ROSDAHL VIBEKE T, ESPERSEN F. The typing of *Staphylococcus epidermis* by a lectin-binding assay, 195
JAY F T, *see* ALFA *et al.*, 413
JENKINSON H F, *see* HOLMES *et al.*, 346
JOENS L A, *see* KONKEL *et al.*, 30
JOHNSON A M, ROBERTS HELEN, TENTER ASTRID M. Evaluation of a recombinant antigen ELISA for the diagnosis of acute toxoplasmosis and comparison with traditional antigen ELISAs, 404
JORDENS J ZOE, *see* MCKENZIE *et al.*, 70

KABIR I, *see* ALBERT *et al.*, 310
KALFAS S, *see* KISHORE *et al.*, 341
KÄLLENIUS G, *see* HOFFNER *et al.*, 332
KAMIKAIDOU N, *see* KITA *et al.*, 326
KAMIYA S, OGURA H, MENG X Q, NAKAMURA S. Correlation between cytotoxin production and sporulation in *Clostridium difficile*, 206
KANWAR J R, VINAYAK V K. The significance of free and immune-complexed hydatid-specific antigen(s) as an immunodiagnostic tool for human hydatidosis, 396
KAPRAL F A, SMITH S, LAL D. The esterification of fatty acids by *Staphylococcus araeus* fatty acid modifying enzyme (FAME) and its inhibition by glycerides, 235
KAPRAL F A, *see* ENGLER AND KAPRAL, 238
KAPRAL F A, *see* LONG *et al.*, 232
KASHIBA S, *see* KITA *et al.*, 326
KATOULI M, KÜHN I, WOLLIN R, MÖLLBY R. Evaluation of the PhP System for biochemical-fingerprint typing of strains of *Salmonella* of serotype Typhimurium, 245
KATOULI M, WOLLIN R, KÜHN I, FARHOUDI-MOGHADDAM A A, MÖLLBY R. The use of biochemical fingerprinting, phage typing and antimicrobial-susceptibility testing in the detection of epidemic strains of *Salmonella* of serotype Typhimurium in Iran, 252
KATSUI N, *see* KITA *et al.*, 326
KATZ S, GROSFELD J L, FOLKENING W J, ROSENTHAL R S, MERKEL G J. Initial organ localisation of blood-borne *Candida albicans* in a rat model of disseminated candidosis, 291
KAZAK R, *see* GLUSKIN *et al.*, 315
KERESTEŠOVÁ A, *see* SIEGFRIED *et al.*, 3
KETLEY J M, *see* EVEREST *et al.*, 319
KISHORE A R, ERDEI J, KALFAS S, FORSGREN A, NAIDU A S. Detection of bacterial interaction with lactoferrin by an enzyme-linked ligand binding assay (ELBA), 341
KISHORE K, RATTAN A, BAGGA A, SRIVASTAVA R N, MANJU NATH N, SHRINIWAS. Serum antibodies to verotoxin-producing *Escherichia coli* (VTEC) strains in patients with haemolytic uraemic syndrome, 364
KITA E, NISHIKAWA F, KAMIKAIDOU N, NAKANO A, KATSUI N, KASHIBA S. Mononuclear cell response in the liver of mice infected with hepatotoxigenic *Campylobacter jejuni*, 326
KMEŤOVÁ M, *see* SIEGFRIED *et al.*, 3
KNUTTON S, *see* EVEREST *et al.*, 319
KONISHI H, ISHIBASHI M, MORSHED M G, NAKAZAWA T. Cytopathic effects of *Helicobacter pylori* on cultured mammalian cells, 118
KONKEL M E, CORWIN M D, JOENS L A, CIEPLAK W. Factors that influence the interaction of *Campylobacter jejuni* with cultured mammalian cells, 30
KRAKOWKA S, *see* EATON *et al.*, 123
KRIKLER S J, LAMBERT P A. Extracellular proteins as a potential marker of active *Staphylococcus aureus* infection in bone, 227
KÜHN I, *see* KATOULI *et al.*, 245, 252
KOWK ANITA Y C, *see* ALFA *et al.*, 413

LAL D, *see* KAPRAL *et al.*, 235
LAMBERT P A, *see* KRIKLER AND LAMBERT, 227
LAMBERT-ZECHOVSKY N, *see* BINGEN *et al.*, 162
LAROCCO H, *see* ASHKENAZI *et al.*, 304
LASTOVICA A J, *see* DA SILVA TATLEY *et al.*, 8
LAW D, WILKIE K M, FREEMAN R, GOULD F K. The iron uptake mechanisms of enteropathogenic *Escherichia coli*: the use of haem and haemoglobin during growth in an iron-limited environment, 15
LEACH A, *see* ALBERT *et al.*, 176
LEE A, *see* TAYLOR *et al.*, 299
LEE Y C, *see* HOLMES *et al.*, 346
LEGAKIS N J, *see* TZELEPI *et al.*, 91
LIGHTFOOT N F, *see* CARTMILL *et al.*, 352
LIMET J N, *see* JACQUES *et al.*, 100
LLOYD D, *see* EVEREST *et al.*, 319
LONG J P, HART J, ALBERS W, KAPRAL F A. The production of fatty acid modifying enzyme (FAME) and lipase by various staphylococcal species, 232
LONON MIRIAM K, *see* STRAUS *et al.*, 335
LOVE H, *see* UDO *et al.*, 180
LUCAS C R, *see* TEE *et al.*, 385

MACIVER I, *see* O'REILLY *et al.*, 133
MCKENZIE H, MORGAN M G, JORDENS J ZOE, ENRIGHT M C, BAIN MARION. Characterisation of hospital isolates of *Moraxella* (*Branhamella*) *catarrhalis* by SDS–PAGE of whole-cell proteins, immunoblotting and restriction-endonuclease analysis, 70
MAGEE J T, HINDMARCH J M, DUERDEN B I, GOODWIN L. Classification of oral pigmented anaerobic bacilli by pyrolysis mass spectrometry and biochemical tests, 56
MAGEE J T, YOUSEFI-MASHOUF R, HINDMARCH J M, DUERDEN B I. A pyrolysis mass spectrometry study of the non-pigmented *Prevotella* species, 273
MANJU NATH N, *see* KISHORE *et al.*, 364
MARDH P-A, *see* NAGY *et al.*, 38
MARPLES R R, *see* DRYDEN *et al.*, 109
MARRE R, *see* SLOOT *et al.*, 201
MARTIN P G, *see* O'REILLY *et al.*, 133
MARTIN S, *see* DRYDEN *et al.*, 109
MARTINI ANNARITA, FILETICI EMMA, FANTASIA MIRELLA. Epidemiological markers of *Salmonella typhimurium* isolates in Rome, 104
MATSUNOSHITA NOBUKO, *see* INOUE *et al.*, 211
MAYALL B, *see* TEE *et al.*, 385
MENG X Q, *see* KAMIYA *et al.*, 206
MENTIS A F, *see* TZELEPI *et al.*, 91
MERKEL G J, *see* KATZ *et al.*, 291

MEYER J K, *see* RILEY *et al.*, 77
MÖLLBY R, *see* KATOULI *et al.*, 245, 252
MOR A, *see* GLUSKIN *et al.*, 315
MORGAN D R, *see* EATON *et al.*, 123
MORGAN M G, *see* MCKENZIE *et al.*, 70
MORSHED M G, *see* KONISHI *et al.*, 118
MOYES A, YOUNG H. An analysis of lectin agglutination as a means of sub-dividing gonococcal serovars, 51
MUÑOZ O, *see* CEDILLO-RIVERA AND MUÑOZ, 221
MURRAY B E, *see* ASHKENAZI *et al.*, 304
MUSILLE V S, *see* RILEY *et al.*, 77

NAGATANI T, *see* SUGITA *et al.*, 357
NAGY ELISABETH, FRÖMAN G, MARDH P-A. Fibronectin binding of *Lactobacillus* species isolated from women with and without bacterial vaginosis, 38
NAIDU A S, *see* KISHORE *et al.*, 341
NAKAJIMA H, *see* SUGITA *et al.*, 357
NAKAMURA S, *see* KAMIYA *et al.*, 206
NAKANO A, *see* KITA *et al.*, 326
NAKAZAWA T, *see* KONISHI *et al.*, 118
NISHIKAWA F, *see* KITA *et al.*, 326
NIVEN D F, *see* O'REILLY *et al.*, 133

OGURA H, *see* KAMIYA *et al.*, 206
OKUDA K, *see* SUGITA *et al.*, 357
OLD D C, Nomenclature of *Salmonella*, 361
O'REILLY T, MACIVER I, POOLE R K, NIVEN D F, MARTIN P G, BROWN M R W. Effect of haemin limitation on the cytochrome complement and glucose metabolism of non-typable *Haemophilus influenzae*, 133
ORR K, *see* CARTMILL *et al.*, 352

PEARSON S, *see* TEE *et al.*, 385
PENNER J L, *see* ALBERT *et al.*, 176
PHILLIPS I, *see* DRYDEN *et al.*, 109
POOLE R K, *see* O'REILLY *et al.*, 133
POUEDRAS P, ANDRE P M, DONNIO P Y, AVRIL J L. Cleavage of immunoglobulin A1, A2 and G by proteases from clinical isolates of *Pasteurella multocida*, 128
PUZOVÁ, *see* SIEGFRIED *et al.*, 3

QADRI F, *see* SAYEED *et al.*, 382

RATTAN A, *see* KISHORE *et al.*, 363
RAYNER R, *see* TEE *et al.*, 385
RICHARDSON J F, *see* DRYDEN *et al.*, 109
RILEY L K, CAFFREY C J, MUSILLE V S, MEYER J K. Cytotoxicity of *Bacillus piliformis*, 77
ROBERTS HELEN, *see* JOHNSON *et al.*, 404
ROBINS-BROWNE R, *see* ALBERT *et al.*, 310
RONALD A R, *see* ALFA *et al.*, 413
ROSDAHL VIBEKE T, *see* JARLØV *et al.*, 195
ROSENTHAL R S, *see* KATZ *et al.*, 291

SACK D A, *see* SAYEED *et al.*, 382
SANYAL S C, *see* SINGH AND SANYAL, 262
SAUNDERS N A, *see* HARRISON *et al.*, 155
SAYEED S, SACK D A, QADRI F. Protection from *Shigella sonnei* infection by immunisation of rabbits with *Plesiomonas shigelloides* (SVC 01), 382
SELLWOOD R, *see* THOMAS AND SELLWOOD, 214
SHAH LATIKA, DAVIES H A, WALL R A. Association of *Haemophilus ducreyi* with cell-culture lines, 268
SHANSON D C, *see* HUTCHINSON *et al.*, 410
SHEPHERD M G, *see* HOLMES *et al.*, 346
SHRINIWAS, *see* KISHORE *et al.*, 364
SIEGFRIED L, PUZOVÁ H, KMEŤOVÁ M, KERESTEŠOVÁ A. Killing of α-haemolytic and non-haemolytic *Escherichia coli* strains in human serum and polymorphonuclear leucocytes, 3
SINGH D V, SANYAL S C. Production of haemolysis and its correlation with enterotoxicity in *Aeromonas* spp., 262
SISSON P R, *see* CARTMILL *et al.*, 352
SLANEY L A, *see* ALFA *et al.*, 413
SLOOT N, THOMAS M, MARRE R, GATERMANN S. Purification and characterisation of elastase from *Staphylococcus epidermidis*, 201
SMITH I, *see* BARCLAY *et al.*, 286
SMITH S, *see* KAPRAL *et al.*, 235
SOOTHILL J S. Treatment of experimental infections of mice with bacteriophages, 258
SRIVASTAVA R N, *see* KISHORE *et al.*, 364
STEYN L M, *see* DA SILVA TATLEY *et al.*, 8
STRAUS D C, LONON MIRIAM K, HUTSON J C. Inhibition of rat alveolar macrophage phagocytic function by a *Pseudomonas cepacia* lipase, 335
SUGITA Y, NAGATANI T, OKUDA K, YOSHIDA Y, NAKAJIMA H. Diagnosis of typhus infection with *Rickettsia tsutsugamushi* by polymerase chain reaction, 357

TALSANIA H G, *see* DRYDEN *et al.*, 109
TAYLOR A G, *see* HARRISON *et al.*, 155
TAYLOR NANCY S, HASUBSKI ANNA T, FOX J G, LEE A. Haemagglutination profiles of *Helicobacter* species that cause gastritis in humans and animals, 299
TEE WEE, MAYALL B, LUCAS C R, RAYNER R, PEARSON S, DWYER B. Use of ribosomal RNA gene restriction patterns to investigate two outbreaks of campylobacter enteritis in Melbourne, Australia, 385
TEE WEE, *see* ALBERT *et al.*, 176
TENTER ASTRID M, *see* JOHNSON *et al.*, 404
THOMAS F D, *see* HUTCHINSON *et al.*, 410
THOMAS M, *see* SLOOT *et al.*, 201
THOMAS W, SELLWOOD R. Monoclonal antibodies to a 16-kDa antigen of *Serpulina* (*Treponema*) *hyodysenteriae*, 214
THOMSON C J, AMYES S G B. Prospects for expanding the use of β-lactamase inhibitors, 297
TSAKRIS A, *see* TZELEPI *et al.*, 91
TZELEPI E, TZOUVELEKIS L S, VATOPOULOS A C, MENTIS A F, TSAKRIS A, LEGAKIS N J. High prevalence of stably derepressed class-1 β-lactamase expression in multiresistant clinical isolates of *Enterobacter cloacae* from Greek hospitals, 91
TZOUVELEKIS L S, *see* TZELEPI *et al.*, 91

UDO E E, LOVE H, GRUBB W B. Intra- and inter-species mobilisation of non-conjugative plasmids in staphylococci, 180

VATOPOULOS A C, *see* TZELEPI *et al.*, 91
VÁZQUEZ J A, *see* DE LA FUENTE AND VÁZQUEZ, 96
VINAYAK V K, *see* KANWAR AND VINAYAK, 396

WADSTRÖM T, *see* CIBOROWSKI *et al.*, 376
WALL R A, *see* SHAH *et al.*, 268
WARNOCK D W. Azole drug resistance in *Candida* species, 225
WEI M-Q, GRUBB W B. Typing of Australian methicillin-resistant *Staphylococcus aureus* strains by pulsed field gel electrophoresis, 187
WEXLER HANNAH M, GETTY C, FISHER G. The isolation and characterisation of a major outer-membrane protein from *Bacteroides distasonis*, 165
WHITE P J, *see* HUSSAIN *et al.*, 62, 368
WILKIE K M, *see* LAW *et al.*, 15
WILLIAMS P H, *see* EVEREST *et al.*, 319
WOLLIN R, *see* KATOULI *et al.*, 245, 252

XIONG Z, KAPRAL F A. Carotenoid pigment levels in *Staphylococcus aureus* and sensitivity to oleic acid, 192

YAKUSHIJI T, *see* INOUE *et al.*, 211
YANG CHUN-LIN, *see* ALFA *et al.*, 412
YOSHIDA Y, *see* SUGITA *et al.*, 357
YOUNG H, *see* MOYES AND YOUNG, 51
YOUSEFI-MASHOUF R, ELEY A, DUERDEN B I. Characterisation of non-pigmented species of the genus *Prevotella* by polyacrylamide gel electrophoresis, 83
YOUSEFI-MASHOUF R, *see* MAGEE *et al.*, 273